NOK 6.93
(0.0%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2021 | 18.46 Million NOK | 18.61% |
2020 | 15.56 Million NOK | 23.6% |
2019 | 12.59 Million NOK | -26.34% |
2018 | 17.09 Million NOK | 16.01% |
2017 | 14.73 Million NOK | 194.56% |
2016 | -15.58 Million NOK | -3.11% |
2015 | -15.11 Million NOK | -1453.28% |
2014 | 1.11 Million NOK | -52.2% |
2013 | 2.33 Million NOK | 299.31% |
2012 | -1.17 Million NOK | -108.65% |
2011 | 13.54 Million NOK | -12.76% |
2010 | 15.52 Million NOK | 27.69% |
2009 | 12.16 Million NOK | -60.94% |
2008 | 31.13 Million NOK | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2021 FY | 18.46 Million NOK | 18.61% |
2020 FY | 15.56 Million NOK | 23.6% |
2019 FY | 12.59 Million NOK | -26.34% |
2018 FY | 17.09 Million NOK | 16.01% |
2017 FY | 14.73 Million NOK | 194.56% |
2016 FY | -15.58 Million NOK | -3.11% |
2016 Q1 | -4.68 Million NOK | 11.38% |
2016 Q2 | 863.14 Thousand NOK | 118.42% |
2016 Q3 | -5.96 Million NOK | -791.47% |
2016 Q4 | -5.79 Million NOK | 2.9% |
2015 FY | -15.11 Million NOK | -1453.28% |
2015 Q3 | -3.23 Million NOK | -4.63% |
2015 Q4 | -5.28 Million NOK | -63.51% |
2015 Q1 | -3.5 Million NOK | -1314.94% |
2015 Q2 | -3.09 Million NOK | 11.77% |
2014 Q3 | -1.5 Million NOK | -173.09% |
2014 Q1 | 812.2 Thousand NOK | 106.92% |
2014 Q2 | 2.05 Million NOK | 152.84% |
2014 FY | 1.11 Million NOK | -52.2% |
2014 Q4 | -247.61 Thousand NOK | 83.5% |
2013 FY | 2.33 Million NOK | 299.31% |
2013 Q4 | -11.73 Million NOK | -7999.19% |
2013 Q3 | -144.93 Thousand NOK | -108.72% |
2013 Q2 | 1.66 Million NOK | 177.8% |
2013 Q1 | -2.13 Million NOK | -219.45% |
2012 Q1 | 3.49 Million NOK | -27.06% |
2012 FY | -1.17 Million NOK | -108.65% |
2012 Q4 | 1.78 Million NOK | 300.01% |
2012 Q3 | 447.03 Thousand NOK | -89.15% |
2012 Q2 | 4.11 Million NOK | 17.76% |
2011 Q1 | 3.17 Million NOK | -32.27% |
2011 Q4 | 4.79 Million NOK | 144.81% |
2011 FY | 13.54 Million NOK | -12.76% |
2011 Q3 | 1.95 Million NOK | -49.7% |
2011 Q2 | 3.89 Million NOK | 22.75% |
2010 Q2 | 4.9 Million NOK | 53.21% |
2010 FY | 15.52 Million NOK | 27.69% |
2010 Q4 | 4.68 Million NOK | 52.33% |
2010 Q1 | 3.2 Million NOK | 0.0% |
2010 Q3 | 3.07 Million NOK | -37.3% |
2009 FY | 12.16 Million NOK | -60.94% |
2008 FY | 31.13 Million NOK | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Arctic Bioscience AS | -5730.00 NOK | 322352.565% |
ArcticZymes Technologies ASA | 97.26 Million NOK | 81.016% |
BerGenBio ASA | 192.17 Million NOK | 90.391% |
Hofseth BioCare ASA | 156.04 Million NOK | 88.167% |
PCI Biotech Holding ASA | 25.23 Million NOK | 26.816% |
Thor Medical ASA | 7.16 Million NOK | -157.856% |
Ultimovacs ASA | 215.73 Million NOK | 91.441% |